Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × 5-aminolevulinic acid hexyl ester × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Colorectal Neoplasms 1

Interventions

Bevacizumab 209 Fluorouracil 199 Irinotecan 192 Oxaliplatin 190 Leucovorin 179 Capecitabine 133 Cetuximab 129 Panitumumab 62 Folfox protocol 45 regorafenib 39 Radiotherapy 37 IFL protocol 35 pembrolizumab 34 HMPL-013 31 trifluridine tipiracil drug combination 28 Nivolumab 27 Neoadjuvant Therapy 24 Drug Therapy 22 tislelizumab 16 Celecoxib 16 aflibercept 15 XELOX 15 Chemotherapy, Adjuvant 15 Trifluridine 14 sintilimab 13 durvalumab 13 atezolizumab 13 Trastuzumab 13 Gemcitabine 13 Floxuridine 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03272659 2019-09-18

PDD

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡